TY - JOUR
T1 - Individualized prevention of proton pump inhibitor related adverse events by risk stratification
AU - Xia, Bin
AU - He, Qiangsheng
AU - Smith, Fang Gao
AU - Gkoutos, V. Georgios
AU - Nirantharakumar, Krishnarajah
AU - Kuo, Zi Chong
AU - Wang, Danni
AU - Feng, Qi
AU - Cheung, Eddie C.
AU - Dai, Lunzhi
AU - Huang, Junjie
AU - Yu, Yuanyuan
AU - Meng, Wenbo
AU - Qin, Xiwen
AU - Yuan, Jinqiu
PY - 2024/4/27
Y1 - 2024/4/27
N2 - Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts from the US, the UK, and China, we found that PPI use correlated with increased risk of 15 leading global diseases, such as ischemic heart disease, diabetes, respiratory infections, and chronic kidney disease. These associations showed dose-response relationships and consistency across different PPI types. PPI-related absolute risks increased with baseline risks, with approximately 82% of cases occurring in those at the upper 40% of the baseline predicted risk, and only 11.5% of cases occurring in individuals at the lower 50% of the baseline risk. While statistical association does not necessarily imply causation, its potential safety concerns suggest that personalized use of PPIs through risk stratification might guide appropriate decision-making for patients, clinicians, and the public.
AB - Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts from the US, the UK, and China, we found that PPI use correlated with increased risk of 15 leading global diseases, such as ischemic heart disease, diabetes, respiratory infections, and chronic kidney disease. These associations showed dose-response relationships and consistency across different PPI types. PPI-related absolute risks increased with baseline risks, with approximately 82% of cases occurring in those at the upper 40% of the baseline predicted risk, and only 11.5% of cases occurring in individuals at the lower 50% of the baseline risk. While statistical association does not necessarily imply causation, its potential safety concerns suggest that personalized use of PPIs through risk stratification might guide appropriate decision-making for patients, clinicians, and the public.
U2 - 10.1038/s41467-024-48007-8
DO - 10.1038/s41467-024-48007-8
M3 - Article
SN - 2041-1723
VL - 15
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 3591
ER -